UK-based surgical guidance company Endomagnetics (Endomag) has secured new financing during a series C round to support the expansion of its magnetic sensing technology to better detect and treat cancer.

The funding round raised $10m and was led by Draper Esprit, the European unit of Draper Venture Network. The new financing brings the company’s total funding to more than $22m.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Endomag aims to leverage magnetic sensing technologies in minimally-invasive surgical guidance to facilitate more accurate targeting and the removal of cancer.

“The company plans to utilise the latest financing to rapidly expand its commercial activity across all markets, as well as to support the planned product development.”

The company primarily focuses on catering to unmet clinical needs in availability, surgical accuracy and workflow efficiency in order to deliver an enhanced experience for breast cancer patients.

It plans to utilise the latest financing to rapidly expand its commercial activity across all markets, as well as to support the planned product development.

Endomag CEO Eric Mayes said: “2018 is shaping up to be the most significant year in Endomag’s history. This funding greatly increases our ability to scale in our primary markets and drive our continued growth.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s portfolio includes Sentimag, Sienna+, Magseed and Siennova. The Sentimag instrument is designed to offer ultrasensitive detection of sentinel lymph nodes in both hospitals and clinics.

Sienna+ is a tracer that generates transient magnetic response to allow the identification of sentinel nodes by using the Sentimag.

Magseed uses Sentimag to guide surgeons during breast lumpectomy. This device is intended to simplify treatment, enhance patient experience and support improved outcomes.

Siennova is a therapeutic hyperthermia system designed for use in combination with chemo- and radiotherapy. Initially, the system is being developed for potential use in bladder cancer therapy.

Till date, Endomag products have been used in more than 35,000 procedures across 300 hospitals in more than 30 countries.